テキストサイズ

  • テキストサイズ 中
  • テキストサイズ 大

JP

検索

EN

Menu

閉じる

分子標的予防医学/保健・予防医学教室(予防医学部門)

 

大学院科目名 分子標的予防医学
医学部教室名 保健・予防医学教室(予防医学部門)
スタッフ
 
 
教授 武藤 倫弘
 
准教授      曽和 義広
講師       渡邉 元樹
助教(学内講師) 飯泉 陽介
助教       増田 光治
研究内容
がん予防剤の実用化に向けたがんハイリスクグループに対する臨床介入試験
 
遺伝子の発現制御機構に基づいた新しいがんの予防法あるいは前がん病変検査・治療法の開発
 
リスク因子や分子機構に基づき、副作用軽減・併用による相互作用・感受性亢進・耐性克服を意図したがん分子標的併用予防法の開発
 
産学連携によるドラッグリポジショニング、機能性食品による予防法の探索と開発
 
ケモプロテオミクス・ケモインフォマティクスによる天然物のがん予防効果の機序解明および新規がん予防成分のin silicoスクリーニングへの展開
 
がん特異的代謝異常に着目した新規がん予防法の開発
 
変異遺伝子による代謝調節に着目した発がん予防物質検索、in vivo有効性評価
 
ケミカルバイオロジーの手法を用いた、がん予防剤や機能性食品成分の標的タンパク質の同定と精密な作用機構解析
 

がん予防教育・啓発に係るD&I(普及と実装)研究

研究業績
Histone deacetylase inhibitor OBP-801 and amrubicin synergistically inhibit the growth of squamous cell lung carcinoma by inducing mitochondrial ASK1-dependent apoptosis.
Chihara Y, Iizumi Y*, Horinaka M, Watanabe M, Goi W, Morita M, Nishimoto E, Sowa Y, Yamada T, Takayama K, Sakai T.
Int J Oncol. 2020; 56: 848-56.
 
Utility of mesalazine in familial adenomatous polyposis: Clinical report of reduction of polyp size in patients with ulcerative colitis, and safety examination in familial adenomatous polyposis patients.
Ishikawa H, Mutoh M*, Abe T, Nakajima T, Takeuchi Y, Ezoe Y, Wakabayashi K, Doyama H, Sakai T.
Pharmacology. 2019; 104(1-2): 51-56.
 
Higher enterococcus counts indicate a lower risk of colorectal adenomas: a prospective cohort study.
Kawano A, Ishikawa H, Mutoh M*, Kubota H, Matsuda K, Tsuji H, Matsumoto K, Nomoto K, Tanaka R, Nakamura T, Wakabayashi K, Sakai T.
Oncotarget. 2018; 9: 21459-67.
 
The histone deacetylase inhibitor OBP-801 and eribulin synergistically inhibit the growth of triple-negative breast cancer cells with the suppression of survivin, Bcl-xL, and the MAPK pathway.
Ono H, Sowa Y*, Horinaka M, Iizumi Y, Watanabe M, Morita M, Nishimoto E, Taguchi T, Sakai T.
Breast Cancer Res Treat. 2018; 171: 43-52.
 
Mevalonate pathway blockage enhances the efficacy of mTOR inhibitors with the activation of retinoblastoma protein in renal cell carcinoma.
Hagiwara N, Watanabe M*, Iizuka-Ohashi M, Yokota I, Toriyama S, Sukeno M, Tomosugi M, Sowa Y, Hongo F, Mikami K, Soh J, Fujito A, Miyashita H, Morioka Y, Miki T, Ukimura O, Sakai T.
Cancer Lett. 2018; 431: 182-9.
 
Blockage of the mevalonate pathway overcomes the apoptotic resistance to MEK inhibitors with suppressing the activation of Akt in cancer cells.
Iizuka-Ohashi M, Watanabe M*, Sukeno M, Morita M, Hoang NTH, Kuchimaru T, Kizaka-Kondoh S, Sowa Y, Sakaguchi K, Taguchi T, Sakai T.
Oncotarget. 2018; 9: 19597-612.
 
Ribosomal protein S3 regulates XIAP expression independently of the NF-κB pathway in breast cancer cells.
Ono H, Iizumi Y*, Goi W, Sowa Y, Taguchi T, Sakai T.
Oncol Rep. 2017; 38: 3205-10.
 
The pleiotropic regulation of cyclin D1 by newly identified sesaminol-binding protein ANT2.
Watanabe M*, Iizumi Y, Sukeno M, Iizuka-Ohashi M, Sowa Y, Sakai T.
Oncogenesis. 2017; 6: e311.
 
Three combined treatments, a novel HDAC inhibitor OBP-801/YM753, 5-fluorouracil, and paclitaxel, induce G₂ phase arrest through the p38 pathway in human ovarian cancer cells.
Akiyama M, Sowa Y*, Taniguchi T, Watanabe M, Yogosawa S, Kitawaki J, Sakai T.
Oncol Res. 2017; 25: 1245-52.
 
Endoscopic management of familial adenomatous polyposis in patients refusing colectomy.
Ishikawa H, Mutoh M*, Iwama T, Suzuki S, Abe T, Takeuchi Y, Nakamura T, Ezoe Y, Fujii G, Wakabayashi K, Nakajima T, Sakai T.
Endoscopy. 2016; 48(1): 51-5.
 
Resveratrol directly targets DDX5 resulting in suppression of the mTORC1 pathway in prostate cancer.
Taniguchi T, Iizumi Y*, Watanabe M, Masuda M, Morita M, Aono Y, Toriyama S, Oishi M, Goi W, Sakai T.
Cell Death Dis. 2016; 7: e2211.
 
Phosphorylated retinoblastoma protein is a potential predictive marker of irinotecan efficacy for colorectal cancer.
Ikai A, Watanabe M, Sowa Y*, Kishimoto M, Yanagisawa A, Fujiwara H, Otsuji E, Sakai T.
Int J Oncol. 2016; 48: 1297-304.
 
Resibufogenin induces G1-phase arrest through the proteasomal degradation of cyclin D1 in human malignant tumor cells.
Ichikawa M, Sowa Y*, Iizumi Y, Aono Y, Sakai T.
PLoS One. 2015; 10: e0129851.
 
The preventive effects of low-dose enteric-coated aspirin tablets on the development of colorectal tumours in Asian patients: a randomised trial.
Ishikawa H, Mutoh M*, Suzuki S, Tokudome S, Saida Y, Abe T, Okamura S, Tajika M, Joh T, Tanaka S, Kudo SE, Matsuda T, Iimuro M, Yukawa T, Takayama T, Sato Y, Lee K, Kitamura S, Mizuno M, Sano Y, Gondo N, Sugimoto K, Kusunoki M, Goto C, Matsuura N, Sakai T, Wakabayashi K.
Gut. 2014 ; 63(11): 1755-9. 
 
The novel HDAC inhibitor OBP-801/YM753 enhances the effects of 5-fluorouracil with radiation on esophageal squamous carcinoma cells.
Furutani A, Sowa Y*, Fujiwara H, Otsuji E, Sakai T.
Oncol Res. 2014; 21: 281-6.
 
Preventive effects of low-dose aspirin on colorectal adenoma growth in patients with familial adenomatous polyposis: double-blind, randomized clinical trial.
Ishikawa H*, Wakabayashi K, Suzuki S, Mutoh M, Hirata K, Nakamura T, Takeyama I, Kawano A, Gondo N, Abe T, Tokudome S, Goto C, Matsuura N, Sakai T.
Cancer Med. 2013; 2: 50-6.
 
The flavonoid apigenin downregulates CDK1 by directly targeting ribosomal protein S9.
Iizumi Y, Oishi M, Taniguchi T, Goi W, Sowa Y, Sakai T.
PLoS One. 2013; 8: e73219.
 
Apigenin sensitizes prostate cancer cells to Apo2L/TRAIL by targeting adenine nucleotide translocase-2.
Oishi M, Iizumi Y, Taniguchi T, Goi W, Miki T, Sakai T.
PLoS One. 2013; 8: e55922.
 
Novel MEK inhibitor trametinib and other retinoblastoma gene (RB)-reactivating agents enhance efficacy of 5-fluorouracil on human colon cancer cells.
Watanabe M, Sowa Y*, Yogosawa M, Sakai T.
Cancer Sci. 2013; 104: 687-93.
Retinoblastoma gene-independent G1 phase arrest by flavone, phosphatidylinositol 3-kinase inhibitor, and histone deacetylase inhibitor.
Tomosugi M, Sowa Y*, Yasuda S, Tanaka R, te Riele H, Ikawa H, Koyama M, Sakai T.
Cancer Sci. 2012; 103: 2139-43.
 
The anti-obesity drug orlistat promotes sensitivity to TRAIL by two different pathways in hormone-refractory prostate cancer cells.
Fujiwara J, Sowa Y*, Horinaka M, Koyama M, Wakada M, Miki T, Sakai T.
Int J Oncol. 2012; 40: 1483-91.
 
Cyclin-dependent kinase inhibitor SU9516 enhances sensitivity to methotrexate in human T-cell leukemia Jurkat cells.
Uchiyama H, Sowa Y*, Wakada M, Yogosawa M, Nakanishi R, Horinaka M, Shimazaki C, Taniwaki M, Sakai T.
Cancer Sci. 2010; 101: 728-34.
 
CDK inhibitor enhances the sensitivity to 5-fluorouracil in colorectal cancer cells.
Takagi K, Sowa Y*, Cevik OM, Nakanishi R, Sakai T.
Int J Oncol. 2008; 32: 1105-10.
 
The plant alkaloid cryptolepine induces p21WAF1/CIP1 and cell cycle arrest in a human osteosarcoma cell line.
Matsui TA, Sowa Y*, Murata H, Takagi K, Nakanishi R, Aoki S, Yoshikawa M, Kobayashi M, Sakabe T, Kubo T, Sakai T.
Int J Oncol. 2007; 31: 915-22.
 
Apigenin induces cell cycle arrest and p21/WAF1 expression in a p53-independent pathway.
Takagaki N, Sowa Y*, Oki T, Nakanishi R, Yogosawa S, Sakai T.
Int J Oncol. 2005; 26: 185-9.
 
p53-independent induction of Gadd45 by histone deacetylase inhibitor: coordinate regulation by transcription factors Oct-1 and NF-Y.
Hirose T, Sowa Y*, Takahashi S, Saito S, Yasuda C, Shindo N, Furuichi K, Sakai T.
Oncogene. 2003; 22: 7762-73.
 
Sp3, but not Sp1, mediates the transcriptional activation of the p21/WAF1/Cip1 gene promoter by histone deacetylase inhibitor.
Sowa Y*, Orita T, Minamikawa-Hiranabe S, Mizuno T, Nomura H, Sakai T.
Cancer Res. 1999; 59: 4266-70.
 
*; corresponding author
問い合わせ先

TEL:075-251-5338
FAX:075-241-0792
e-mail:prevpub@koto.kpu-m.ac.jp

〒602-8566. 京都市上京区河原町通広小路上る梶井町465

お問い合わせ先
TEL:075-251-5111
FAX:075-211-7093